Weight Loss Through Bombesin - Controlled Appetite Regulation
Recent fire research seems to highlight the role of these hormones in weight loss, appetite control and metabolism, and suggest new drugs that have the potential to control obesity. The discovery of these mechanisms, such as the action of other key metabolic control mechanisms (the effect of insulin on blood sugar storage, or leptin on metabolism) may play a major role in the combination of drugs. Although the new drug may be relatively small, the results reported are encouraging. Obesity is usually controlled through (1) behavioral modifications, such as reduced eating habits, increased physical activity, or (2) through surgical intervention.
Obesity seems to be under control by the use of drugs, which drives researchers to develop new solutions. Xao-Ming Guan and co-researchers wanted to explore the function of a cell called Bombesin Receptor Subtype-3 (or BSR-3). The author writes that despite its name, it has a relatively poor ability to receive bombesine messages.
For the purpose of their experiments, the authors used two new compounds to increase or decrease the action of bombesin on the BSR-3 receptor. The findings are:
- Applying antagonist ligand compounds results in an increase in food intake, with increased weight gain. Because the action of bombesin is to reduce appetite, the application of antagonist ligands naturally inhibits this action, and is expected to have such an effect.
- The use of agonist ligands, resulting in a decrease in the amount of food consumed, and an increase in metabolic rate. An additional positive factor is that the agonist compound is given to the laboratory animal orally. This may be the ideal drug distribution method for most human patients (as it does not require other types of delivery such as shots or clinical visits). The authors also reported that agonist action was found to be different from other metabolic pathways, suggesting that BRS-3-type therapy may be combined with other therapies for greater efficacy.
------------------
No comments